Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Neuraminidase inhibitors for influenza: a review and public health perspective in the aftermath of the 2009 pandemic.

Beck CR, Sokal R, Arunachalam N, Puleston R, Cichowska A, Kessel A, Zambon M, Nguyen-Van-Tam JS; UK Antiviral Effectiveness Review Group.

Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:14-24. doi: 10.1111/irv.12048. Review.

2.

Neuraminidase inhibitors for preventing and treating influenza in healthy adults.

Jefferson T, Jones M, Doshi P, Del Mar C, Dooley L, Foxlee R.

Cochrane Database Syst Rev. 2010 Feb 17;(2):CD001265. doi: 10.1002/14651858.CD001265.pub3. Review.

PMID:
20166059
3.

Neuraminidase inhibitors for preventing and treating influenza in children.

Wang K, Shun-Shin M, Gill P, Perera R, Harnden A.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD002744. doi: 10.1002/14651858.CD002744.pub3. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD002744.

PMID:
22258949
4.

Neuraminidase inhibitors for preventing and treating influenza in healthy adults.

Jefferson TO, Demicheli V, Di Pietrantonj C, Jones M, Rivetti D.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001265. Review.

PMID:
16855962
5.

Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis.

Jefferson T, Jones M, Doshi P, Del Mar C.

BMJ. 2009 Dec 8;339:b5106. doi: 10.1136/bmj.b5106. Review.

6.

Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.

Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, Hama R, Thompson MJ.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD008965. doi: 10.1002/14651858.CD008965.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;4:CD008965.

PMID:
22258996
7.

Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation.

Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R, Nicholson K.

Health Technol Assess. 2009 Feb;13(11):iii, ix-xii, 1-246. doi: 10.3310/hta13110. Review.

8.

Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors for patients with pandemic influenza H1N1 2009 or seasonal H1N1 influenza in the 2007-2008 and 2008-2009 seasons.

Kawai N, Ikematsu H, Tanaka O, Matsuura S, Maeda T, Yamauchi S, Hirotsu N, Nishimura M, Iwaki N, Kashiwagi S.

J Infect Chemother. 2011 Jun;17(3):375-81. doi: 10.1007/s10156-010-0179-9. Epub 2010 Dec 1.

PMID:
21120678
9.

Neuraminidase inhibitors for preventing and treating influenza in children.

Matheson NJ, Symmonds-Abrahams M, Sheikh A, Shepperd S, Harnden A.

Cochrane Database Syst Rev. 2003;(3):CD002744. Review. Update in: Cochrane Database Syst Rev. 2007;(1):CD002744.

PMID:
12917931
10.

[French general practitioners' perceptions and use of neuraminidase inhibitors during the pandemic A(H1N1)2009 influenza].

Barthe J, Noyelle C, Partouche H.

Sante Publique. 2011 Jul-Aug;23(4):305-15. French.

PMID:
22177608
11.

Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials.

Shun-Shin M, Thompson M, Heneghan C, Perera R, Harnden A, Mant D.

BMJ. 2009 Aug 10;339:b3172. doi: 10.1136/bmj.b3172. Review.

12.

Antivirals for influenza in healthy adults: systematic review.

Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A.

Lancet. 2006 Jan 28;367(9507):303-13. Review. Erratum in: Lancet. 2006 Jun 24;367(9528):2060.

PMID:
16443037
13.

[Neuraminidase inhibitors oseltamivir and zanamivir: new means of defence against influenza].

de Jong JC, Beyer WE, Rimmelzwaan GF, Fouchier RA, Osterhaus AD.

Ned Tijdschr Geneeskd. 2004 Jan 10;148(2):73-9. Review. Dutch. Erratum in: Ned Tijdschr Geneeskd. 2004 Feb 14;148(7):348.

PMID:
14753128
14.

Antiviral drugs in influenza: an adjunct to vaccination in some situations.

[No authors listed]

Prescrire Int. 2006 Feb;15(81):21-30.

PMID:
16548114
15.

Developments in the treatment of severe influenza: lessons from the pandemic of 2009 and new prospects for therapy.

Zambon M.

Curr Opin Infect Dis. 2014 Dec;27(6):560-5. doi: 10.1097/QCO.0000000000000113. Review.

PMID:
25333476
16.

Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.

Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K.

Health Technol Assess. 2003;7(35):iii-iv, xi-xiii, 1-170. Review.

17.

Clinical use of approved influenza antivirals: therapy and prophylaxis.

Ison MG.

Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:7-13. doi: 10.1111/irv.12046. Review.

18.

[The use of antiviral agents during an (impending) influenza pandemic].

Opstelten W, van Steenbergen JE, van Essen GA, Van der Sande MA.

Ned Tijdschr Geneeskd. 2007 May 5;151(18):1008-12. Review. Dutch.

PMID:
17508684
19.
20.

Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients.

Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS.

J Infect Dis. 2013 Feb 15;207(4):553-63. doi: 10.1093/infdis/jis726. Epub 2012 Nov 29. Review.

Supplemental Content

Support Center